Starpharma (ASX: SPL, OTCQX: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient.
Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.
Starpharma has developed a valuable technology platform known as DEP® (Dendrimer Enhanced Product), which utilises dendrimers to improve drug performance, effectiveness and safety. This innovative approach opens new possibilities for targeted and controlled drug delivery, increasing therapeutic and commercial opportunities. Additionally, the use of DEP® technology can create new intellectual property and proprietary products, extending the patent life for existing drugs.
The DEP® platform is highly versatile with broad applicability across multiple oncology approaches, including cancer drugs such as chemotherapeutics, antibody-drug conjugates (ADCs), radiotheranostics, antivirals, and other non-oncology molecules. Illustrating the value of DEP® and through its innovative approach, Starpharma has established DEP® partnerships with some of the world’s largest pharmaceutical companies and leading research institutes.
Starpharma has also developed an innovative proprietary anti-infective dendrimer called SPL7013, which has a physical mechanism of action and antiviral and antimicrobial properties. With this antimicrobial dendrimer SPL7013, Starpharma has successfully developed and launched three products in specific markets. The SPL7013 product range includes an antiviral nasal spray for cold/respiratory viruses, a topical gel for the treatment and prevention of recurrent bacterial vaginosis (BV), and an antiviral condom for sexually transmitted infections (STIs).
By leveraging its patented dendrimer technology, Starpharma strives to create innovative healthcare solutions that are commercially attractive and beneficial to patients, doctors, and healthcare providers.
